E
Lixte Biotechnology Holdings, Inc. LIXT
$1.26 $0.000.00% NASDAQ
Recommendation
Prev Close
$1.26
Volume
585
Avg Vol (90D)
50,136
Market Cap
$3.38M
Dividend & Yield
--
52-Week Range
$1.02 - $3.50
P/E (TTM)
--
EPS (TTM)
-$1.59
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
3/31/2025 - Globe Newswire
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
3/27/2025 - Globe Newswire
New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form
3/10/2025 - Globe Newswire
LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
2/25/2025 - Globe Newswire
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2/13/2025 - Globe Newswire
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2/11/2025 - Globe Newswire
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
2/10/2025 - Globe Newswire
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
9/11/2024 - Accesswire
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
9/11/2024 - Accesswire
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
9/4/2024 - Globe Newswire
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Increase in Short Interest
9/2/2024 - Ticker Report
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update
8/31/2024 - Zolmax
First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
8/26/2024 - Globe Newswire
LIXTE Biotechnology Provides Update On Recent Activities and Developments
8/19/2024 - Globe Newswire
LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024
8/17/2024 - InvestorPlace
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
8/15/2024 - Globe Newswire
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
8/15/2024 - Accesswire
Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Decreases By 12.9%
7/15/2024 - Zolmax
Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Declines By 12.9%
7/14/2024 - Ticker Report
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
6/14/2024 - Globe Newswire
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
6/14/2024 - Globe Newswire
Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
6/6/2024 - Globe Newswire
Lixte Biotechnology Appoints New Chief Medical Officer
6/5/2024 - TipRanks Financial Blog
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
6/3/2024 - Globe Newswire
LIXTE Biotechnology Holdings Provides Update on Recent Activities
5/20/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$3.57M
Net Income (TTM)
-$3.59M
Balance Sheet
Total Assets (Q)
$1.15M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$318.30K
Book Value Per Share (Q)
-$1.19
Cash Flow
Cash from Operations (TTM)
-$3.16M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
-$3.16M
Filings
Filing Date
Monday, March 24, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.70
7-Day Total Return
7.69%
30-Day Total Return
3.28%
60-Day Total Return
-56.28%
90-Day Total Return
-34.03%
Year to Date Total Return
-43.24%
1-Year Total Return
-56.25%
2-Year Total Return
-77.50%
3-Year Total Return
-90.87%
5-Year Total Return
-97.64%
52-week Low
Mar 12, 2025 - $1.02
52-week High
Jun 14, 2024 - $3.50
Valuation
Market Cap
$3.38M - Nano Cap
Enterprise Value
$5.84M
Price/Sales (TTM)
--
Price/Book (Q)
-1.06
Dividends and Shares
Shares Outstanding
2.25M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
lixte.com
Phone Number
631 830 7092
Address
680 East Colorado Boulevard
Pasadena, CA 91101
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies... more
NASDAQ 05/01/2025 10:23AM Eastern Quotes delayed